Due to NGF’s low bioavailability and its impermeability through the blood–brain-barrier, it has been considered that the use of NGF as a potential therapeutic agent against neurodegenerative diseases, including AD, was limited. The gene discussed is NGF; the disease is neurodegenerative disease.